Analysts Anticipate Kindred Biosciences Inc (NASDAQ:KIN) Will Post Quarterly Sales of $1.45 Million

Wall Street analysts predict that Kindred Biosciences Inc (NASDAQ:KIN) will report sales of $1.45 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Kindred Biosciences’ earnings, with estimates ranging from $1.40 million to $1.50 million. Kindred Biosciences reported sales of $1.33 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9%. The company is scheduled to issue its next earnings report on Wednesday, March 4th.

According to Zacks, analysts expect that Kindred Biosciences will report full year sales of $4.27 million for the current fiscal year, with estimates ranging from $4.13 million to $4.40 million. For the next financial year, analysts expect that the company will post sales of $10.97 million, with estimates ranging from $8.80 million to $13.14 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%.

KIN has been the subject of several recent research reports. BidaskClub raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. ValuEngine raised Kindred Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective (down previously from $17.50) on shares of Kindred Biosciences in a research note on Wednesday, November 13th. Finally, Zacks Investment Research raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, November 16th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $13.94.

Shares of KIN stock traded up $0.05 on Thursday, reaching $7.82. The company had a trading volume of 75,414 shares, compared to its average volume of 175,508. The business’s 50-day moving average is $8.01 and its 200 day moving average is $7.63. Kindred Biosciences has a one year low of $5.96 and a one year high of $12.99. The company has a quick ratio of 8.88, a current ratio of 9.30 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $304.51 million, a PE ratio of -4.89 and a beta of 0.42.

A number of large investors have recently added to or reduced their stakes in KIN. Marshall Wace LLP acquired a new stake in Kindred Biosciences during the 1st quarter valued at approximately $53,000. Aperio Group LLC acquired a new stake in Kindred Biosciences during the 2nd quarter valued at approximately $115,000. General American Investors Co. Inc. increased its position in Kindred Biosciences by 10.0% during the 2nd quarter. General American Investors Co. Inc. now owns 494,327 shares of the biopharmaceutical company’s stock valued at $4,118,000 after purchasing an additional 44,753 shares during the period. Gabelli Funds LLC acquired a new stake in Kindred Biosciences during the 2nd quarter valued at approximately $108,000. Finally, PARK CIRCLE Co acquired a new stake in Kindred Biosciences during the 2nd quarter valued at approximately $27,000. 67.37% of the stock is owned by institutional investors and hedge funds.

About Kindred Biosciences

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Recommended Story: Put Option Volume

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.